Eger

• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending
  2025-521037-86-00 5 Immune system diseases
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Pending
  2025-521038-27-00 5 Immune system diseases
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Pending
  2025-522511-42-00 4 Crohn's disease
• An efficacy and safety study of cenegermin ophthalmic solution compared with vehicle in the treatment of PCED Pending
  2025-523443-35-00 5 Persistent Corneal Epithelial Defect (PCED)
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting
  2024-514499-42-00 5 2025-03-12 Refractory Partial Onset Epilepsy
• A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with a … Recruiting
  2023-509606-30-00 5 2024-07-24 Ulcerative colitis
• A Phase 3, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil and Contezolid Compared … Recruiting
  2022-500257-16-00 5 2023-03-17 Diabetic Foot Infections
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting
  2025-521416-19-00 4 2026-03-12 Recurrence of Clostridioides difficile Infection
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis Recruiting
  2025-521035-37-00 5 2026-03-02 Immune system diseases
• Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting
  2025-521382-27-00 10 2025-12-04 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• International study to compare the efficacy and safety of chondroitin sulfate 800 mg tablets of two different origins (bovine versus marine) … Recruiting
  2024-516337-12-00 5 2025-08-07 Knee osteoarthritis with moderate to severe pain
• A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting
  2024-517335-46-00 4 2025-06-05 Bladder cancer
• A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti … Recruiting
  2024-513053-69-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting
  2024-512633-32-00 4 2025-04-07 Crohn's disease
• Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting
  2024-513853-66-00 5 2025-02-04 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
• Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc … Recruiting
  2024-513852-13-00 5 2025-01-20 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Col
• A Phase 2/3 study to evaluate safety and efficacy of the combination of Bel- CHOP/ Fol-COP drugs against CHOP in newly diagnosed Peripheral … Recruiting
  2023-507803-76-00 10 2024-09-26 Peripheral T-Cell Lymphoma
• A Phase 2 Study to Evaluate MORF-057 in Adults with Moderately to Severely Active Crohn’s Disease Recruiting
  2023-508158-24-00 4 2024-06-25 Moderately to Severely Active Crohn’s Disease
• Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy … Recruiting
  2022-500531-36-00 4 2024-02-02 Type 1 diabetes mellitus
• A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o … Recruiting
  2022-502193-16-00 5 2023-11-14 Chronic lymphocytic leukemia, Multiple Myeloma and Non-Hodgkin Lymphom

Showing 1–24 of 60 trials